Evidence map›Paper›PMID 35578210›Full record

ArticleBMC cancer2022

Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors.

Yasuki Uchida, Daisuke Kinose, Yukihiro Nagatani, Sachiko Tanaka-Mizuno, Hiroaki Nakagawa, Kentaro Fukunaga, Masafumi Yamaguchi, Yasutaka Nakano

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Pulmonary toxicity of immune checkpoint inhibitors.Breathe (Sheffield, England) · 2026
    Review
  2. Article
  3. Article
  4. Clinical management of checkpoint inhibitor pneumonitis: Focus, challenges, and future directions.Chinese medical journal pulmonary and critical care medicine · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yasuki UchidaDivision of Respiratory Medicine, Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan. uchiy@belle.shiga-med.ac.jp.
Daisuke KinoseDivision of Respiratory Medicine, Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan.
Yukihiro NagataniDepartment of Radiology, Shiga University of Medical Science, Otsu, Japan.
Sachiko Tanaka-MizunoDepartment of Digital Health and Epidemiology, Kyoto University, Kyoto, Japan.
Hiroaki NakagawaDivision of Respiratory Medicine, Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan.
Kentaro FukunagaDivision of Respiratory Medicine, Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan.
Masafumi YamaguchiDivision of Respiratory Medicine, Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan.
Yasutaka NakanoDivision of Respiratory Medicine, Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan.
Shiga University of Medical Science · JPKyoto University · JPTaoka Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune-mediated pneumonitis has a high mortality rate; however, information regarding the related risk factors remains limited. This study aimed to analyze risk factors for pneumonitis, including smoking and lung metastasis (LM), in patients with extrapulmonary primary tumors.

methodsData of 110 patients treated with immune checkpoint inhibitors (ICIs) (nivolumab/pembrolizumab) for treating extrapulmonary primary tumors at the Shiga University of Medical Science Hospital between January 2015 and December 2019 were retrospectively collected. The association between the onset of pneumonitis and treatment-related factors was analyzed by logistic regression. The severity of pneumonitis was graded according to the Common Terminology Criteria for Adverse Events version 5.0. Risk factors, such as the absence or presence of interstitial lung disease (ILD) and LM, or other clinical factors, including smoking status before ICI administration, were analyzed.

resultsMultivariate analyses indicated that the amount of smoking was significantly associated with an increase in the development of all-grade pneumonitis types (odds ratio (OR) = 20.33, 95% confidence interval (CI) = 20.03-20.66; p = 0.029). LM and ILD were significantly related to an increase in the development of symptomatic pneumonitis (≥ Grade 2) (OR = 10.08, 95% CI = 1.69-199.81; p = 0.076, and OR = 6.76, 95% CI = 1.13-40.63; p = 0.037, respectively).

conclusionsPre-screening for ILD and LM and recognizing patients' smoking history is important for determining the risk of ICI-induced pneumonitis and allowing safe ICI administration.

Indexed as

Lung Diseases, InterstitialLung NeoplasmsPneumoniaHumansImmune Checkpoint InhibitorsRetrospective StudiesRisk FactorsImmune Checkpoint InhibitorsExtrapulmonary tumorImmune checkpoint inhibitorsLung metastasisNivolumabPembrolizumabPneumonitis

Identifiers

PMID35578210
PMCPMC9109739
OpenAlexW4280541322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.